NCT04580771View on ClinicalTrials.gov

A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 14, 2020

Primary Completion Date

March 8, 2027

Study Completion Date

March 8, 2027

Conditions
Locally Advanced Cervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage IB3 Cervical Cancer FIGO 2018Stage II Cervical Cancer FIGO 2018Stage IIA Cervical Cancer FIGO 2018Stage IIA1 Cervical Cancer FIGO 2018Stage IIA2 Cervical Cancer FIGO 2018Stage IIB Cervical Cancer FIGO 2018Stage III Cervical Cancer FIGO 2018Stage IIIA Cervical Cancer FIGO 2018Stage IIIB Cervical Cancer FIGO 2018Stage IIIC Cervical Cancer FIGO 2018Stage IIIC1 Cervical Cancer FIGO 2018Stage IIIC2 Cervical Cancer FIGO 2018Stage IVA Cervical Cancer FIGO 2018
Interventions
DRUG

Cisplatin

Given IV

BIOLOGICAL

Liposomal HPV-16 E6/E7 Multipeptide Vaccine PDS0101

Given SC

RADIATION

Radiation Therapy

Undergo radiation therapy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER